Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Reductions in blood glucose levels in people with diabetes are often achieved at the expense of increased hypoglycemia. A novel approach is to automatically deliver microdose glucagon when automation of insulin delivery alone is not sufficient to prevent hypoglycemia. The approach requires a bihormonal device and a stable form of glucagon or glucagon analog. The iLet bionic pancreas (Beta Bionics, Inc.) is a purpose-built, fully integrated device that receives a signal from a continuous glucose monitor (CGM) and contains autonomous, lifelong learning, mathematical dosing algorithms, which are initialized only with the patient’s body weight (1). We evaluated the function and safety of the iLet in both its insulin-only configuration and its bihormonal configuration delivering dasiglucagon, a chemically stable glucagon analog (Zealand Pharma), in a home-use study in adults with type 1 diabetes (T1D). This open-label, random-order, crossover, home-use trial (clinical trial reg. no. NCT03840278, ClinicalTrials.gov) was the first human study to test the bihormonal iLet configuration and the first multiday use of dasiglucagon in people with T1D (2). Ten participants used the insulin-only iLet for 7 days with insulin lispro (Eli Lilly) or aspart (Novo Nordisk), the bihormonal iLet for 7 days with dasiglucagon (4 mg/mL) and insulin lispro or aspart, or both, using the same glucose target (110 mg/dL), in random order. There were no restrictions on diet or exercise. The primary outcomes were prespecified iLet operational thresholds. The key secondary outcome was the median time with CGM glucose <54 mg/dL on days 2–7 (after one day of adaptation). All participants completed the study. …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Hövelmann, U., Bysted, B. V., Mouritzen, U., Macchi, F., Lamers, D., Kronshage, B., Møller, D. V., & Heise, T. (2018) · Diabetes Care · doi:10.2337/dc17-1402 · Cited by 115 · cited 3×
“NCT03840278, ClinicalTrials.gov) was the first human study to test the bihormonal iLet configuration and the first multiday use of dasiglucagon in people with T1D (2).”
BackgroundInfluential
Cited by
Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., et al. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac022 · Cited by 443
Self-citationKovatchev, B. P., Singh, H., Mueller, L., & Gonder-Frederick, L. A. (2022) · Diabetes Care · doi:10.2337/dc22-1217 · Cited by 49
“Several other systems are at various stages in their development, Diabeloop (14), Tidepool Loop (15), the bihormonal artificial pancreas (insulin plus glucagon) from Inreda Diabetic (16), and iLet, in two configurations, insulin only and insulin plus glucagon (17).”
BackgroundBionic Pancreas Research Group, Beck, R. W., Russell, S. J., Damiano, E. R., El-Khatib, F. H., Ruedy, K. J., Balliro, C., Li, Z., & Calhoun, P. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0167 · Cited by 40
Self-citationA New Role for Glucagon: From Secondary Hormone to Key Player
De Fano, M., Malara, M., Rucco, S., Manco, M., Fanelli, C. G., Bolli, G. B., & Porcellati, F. (2025) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104233 · Cited by 1
Metadata
- Authors
- Castellanos, L. E., Balliro, C. A., Sherwood, J. S., Jafri, R., Hillard, M. A., Greaux, E., Selagamsetty, R., Zheng, H., El-Khatib, F. H., Damiano, E. R., & Russell, S. J.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-06-01
- Volume
- 44
- Issue
- 6
- Pages
- e118-e120
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W3157605032
- Cited by
- 74
- References
- 2
- FWCI
- 8.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting. https://app.cochat.ai/papers/10.2337/dc20-1086
- The paper
- Castellanos, L. E., Balliro, C. A., Sherwood, J. S., Jafri, R., Hillard, M. A., Greaux, E., Selagamsetty, R., Zheng, H., El-Khatib, F. H., Damiano, E. R., & Russell, S. J. (2021). Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting. Diabetes Care. https://doi.org/10.2337/dc20-1086
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.